22/100Is SLS-SELLAS Life Sciences Group, a buy?
Monday 14 September 2026
Why now: The current 4.5% rebound to $12.06 follows a weak daily setup and comes ahead of consequential clinical milestones. The timing matters because the Phase 3 REGAL result can reset the company’s value, but the bounce does not repair the underlying technical damage.
Upside: The five-firm analyst consensus target is $35, implying about 190% upside from the current price. That implied return depends on successful REGAL data, regulatory progress, and a credible commercial path from a company with no product revenue.
Risks: A negative or unclear REGAL result could erase much of the current valuation quickly. Further share issuance remains a serious risk after five-year share growth of 1,267% and the availability of an at-the-market equity facility.
Sign up or log in for access
Unlock the full scorecard, detailed analysis, and research notes. Free — no credit card needed.
Scorecard
| Scorecard | 22/100 | |
|---|---|---|
| Company Detail | SLS - SELLAS Life Sciences Group, Inc. | |
| Price as at 14 September 2026 | $12.06 | |
| Market cap | $2.2B | |
| Quality and Fundamental Score (100) | ||
| Breakout / Early-Momentum /20 | 1/20 | |
| Rev/EPS Momentum /20 | 0/20 | |
| Business Quality /15 | 4/15 | |
| Balance Sheet /15 | 3/15 | |
| Valuation /10 | 0/10 | |
| Industry Relative Strength /10 | 10/10 | |
| Macro / Sector Tailwind /10 | 4/10 | |
| Growth | ||
| Cash runway | 4.9 yr | |
| Revenue YoY | — | |
| EPS YoY | +50.0% | |
| FCF YoY | +19.8% | |
| Gross margin | 90.0% | |
| Valuation & Trend | ||
| Trailing P/E | neg | |
| Forward P/E | — | |
| RSI (14d) | 44 | |
| vs 50d SMA | -4.9% | |
| Support cushion | −10.0% | |
| Sentiment | ||
| Wall Street verdict | Mixed | |
| News tone | Quiet | |
| Dividend | — | |
How are these colored?
| Metric | Strong metrics | Solid metrics | Selective | Caution | Unfavourable |
|---|---|---|---|---|---|
| Overall score | ≥ 80 | 70-79 | 60-69 | 50-59 | < 50 |
| Business quality /15 | ≥ 12 | 10-11 | 8-9 | 6-7 | < 6 |
| Balance sheet /15 | ≥ 12 | 10-11 | 8-9 | 6-7 | < 6 |
| Market cap | ≥ $20B | $5B-$20B | $2B-$5B | $1B-$2B | < $1B |
| Cash runway | ≥ 3 yr or cash generative | 1.5-3 yr | 0.75-1.5 yr | 0.25-0.75 yr | < 0.25 yr |
| Revenue YoY | ≥ 15% | 5-15% | 0-5% | -5-0% | < -5% |
| EPS YoY | ≥ 20% | 5-20% | 0-5% | -5-0% | < -5% |
| FCF YoY | ≥ 10% | 1-10% | 0-1% | -5-0% | < -5% |
| Gross margin | ≥ 60% | 40-60% | 25-40% | 10-25% | < 10% |
| Trailing P/E | < 15 | 15-25 | 25-35 | 35-40 | > 40 or neg |
| Forward P/E | < 15 | 15-25 | 25-35 | 35-40 | > 40 or neg |
| RSI (14d) | 50-70 | 45-50 or 70-75 | 40-45 or 75-78 | 30-40 or 78-80 | < 30 or > 80 |
| vs 50d SMA | +2% to +15% | 0-2% or 15-25% | -2-0% or 25-35% | -3--2% or 35-40% | < -3% or > 40% |
| Support cushion | 2-10% above | 0-2% | 10-15% | 15-20% | price below support |
| Wall Street verdict | Aligned | — | Mixed | — | Disagrees |
| News tone | Positive | — | Neutral / Mixed | — | Negative |
| Dividend | Yield ≥ 2% & growing | Growing | Flat payer ≥ 1% | Low / flat | Cutting |
Detailed Analysis — Monday 14 September 2026
Angelos M.
John Thomas Burns has served as Senior Vice President and Chief Financial Officer since February 2023.
Receiver of capital expenditure: No: SELLAS is not a receiver of customer capital expenditure because it is developing unapproved medicines and does not yet sell commercial products.
Main customers
- Acute myeloid leukemia treatment market (GPS is being evaluated for patients who achieved remission after second-line salvage treatment.)
- Newly diagnosed acute myeloid leukemia treatment market (SLS009 is in an 80-patient study that includes patients with early resistance to azacitidine and venetoclax treatment.)
Notable contracts
- Memorial Sloan Kettering Cancer Center license (Exclusive global agreement for development, marketing, and commercialization of the GPS Wilms tumor 1 immunotherapy.)
- GenFleet Therapeutics license (Exclusive agreement covering development, manufacturing, and commercialization of SLS009 outside Greater China.)
- 3D Medicines GPS license (3D Medicines holds Greater China rights for GPS; SELLAS's arbitration claims against 3D Medicines were dismissed in July 2026.)
- SELLAS has two oncology programs aimed at areas with meaningful unmet need, and GPS is nearing the final analysis stage of its pivotal acute myeloid leukemia study.
- The company also has enough cash to continue operating for several years based on its current cash-use profile.
- However, the investment case is not based on an operating business today; it is a concentrated bet that unapproved medicines deliver positive clinical and regulatory outcomes before dilution absorbs the potential value.
Scores 22 out of 100. a mixed overall grade. Relative strength versus its industry scored highest. Sector fit and business quality weighed on the total. The score is capped by the absence of product revenue, recurring losses, a binary Phase 3 trial outcome, very large five-year share dilution, and an active equity-sale facility. The manual nomination requires research coverage, but the current facts do not support a high-quality long-term score. Mechanical cap: latest annual net income ≤ 0. Balance Sheet ≤ 3/15, Rev/EPS ≤ 0/20, overall ≤ 50/100.
Component scores are on the scorecard above.
- SLS remains below its 50-day moving average and has no confirmed breakout, with a low mechanical pre-breakout score and average volume that is not expanding.
- The last completed daily bar showed a 5.6% decline over 20 trading days despite a 147.6% gain over 90 trading days, while the live price rebound to $12.06 is constructive for the day but still well below the $15.67 resistance level.
- Its 200-day moving average is rising and industry relative strength is strong, but those positives do not overcome the failed 50-day reclaim.
- SELLAS reported no annual revenue, a $26.86 million annual net loss, and negative free cash flow of $28.39 million.
- Second-quarter research and development expense rose as the company prepared for a potential filing after REGAL, while the quarterly loss widened to $9.6 million.
- Cash of $138.44 million and very low liabilities provide a substantial funding cushion, but the company has no commercial income, negative returns on capital, and a history of substantial shareholder dilution.
- The July dismissal of its arbitration claims against 3D Medicines also weakened a potential partnership-payment source and added legal costs.
Cash runway: 4.9 yr ($138M cash ÷ $28M/yr burn, latest fiscal year).
Upcoming (1–6 months)
- Announcement that the pre-specified 80th event has occurred in the Phase 3 REGAL study, followed by the final data analysis and topline result.
- Topline data expected in the fourth quarter of 2026 from the ongoing SLS009 study in newly diagnosed acute myeloid leukemia.
Ongoing
- Cash use, any sales under the at-the-market equity facility, and the share count following future financing activity.
Risks
- REGAL may fail to show the required benefit, and an oncology Phase 3 failure would leave the valuation dependent on earlier-stage SLS009 work.
- Further equity issuance can dilute existing holders, while the dismissed 3D Medicines arbitration reduces confidence in partnership-related cash inflows.
Breaks the thesis
- A negative, delayed, or clinically ambiguous REGAL final analysis invalidates the central near-term value case.
- A daily close below $11.54 after the current rebound would erase the September 14 price recovery and confirm that the weak technical trend remains intact.